Literature DB >> 9506575

The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis.

N Menon1, L McAlpine, A J Peacock, R Madhok.   

Abstract

OBJECTIVE: To determine whether patients with isolated pulmonary hypertension secondary to systemic sclerosis (SSc) have a pulmonary vasculature that is responsive to treatment with vasodilators.
METHODS: Seven SSc patients with pulmonary hypertension underwent right heart catheterization. Pulmonary pressures and cardiac output were measured before and during a systemic intravenous infusion of prostacyclin.
RESULTS: Both pulmonary arterial mean pressure and pulmonary vascular resistance decreased significantly with prostacyclin infusion (median decrease 11% and 32%, respectively), with a concomitant increase in cardiac output (median increase 26%). No adverse hemodynamic effects were noted during the infusion.
CONCLUSION: Vasospasm contributes to the pulmonary hypertension complicating SSc. This feature may be amenable to treatment with vasodilators.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506575     DOI: 10.1002/1529-0131(199803)41:3<466::AID-ART13>3.0.CO;2-O

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

Review 1.  Prostacyclin for pulmonary hypertension in adults.

Authors:  N S Paramothayan; T J Lasserson; A U Wells; E H Walters
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 2.  Novel therapeutic strategies in scleroderma.

Authors:  C P Denton; C M Black
Journal:  Curr Rheumatol Rep       Date:  1999-10       Impact factor: 4.592

Review 3.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

4.  Diagnosis and management of pulmonary arterial hypertension.

Authors:  Jeanne Houtchens; Douglas Martin; James R Klinger
Journal:  Pulm Med       Date:  2011-09-20

Review 5.  Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH).

Authors:  Rahul G Argula; Celine Ward; Carol Feghali-Bostwick
Journal:  Ther Clin Risk Manag       Date:  2019-12-13       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.